Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AART
NCT00332657Phase 3Terminated
- Sponsor
- Alcon Inc.
- Start
- Sep 2006
- Primary completion
- Dec 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anecortave in age-related macular degeneration (AMD) (3 arms), sponsored by Alcon Inc. Primary endpoint: Proportion of patients with sight-threatening choroidal neovascularization (CNV) in study eye at Month 48. Started Sep 2006; status: terminated.
02
Drugs
anecortave
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00332657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00332657.